We will work closely with our customers and business partners to achieve and maintain a leading market position, offering high-quality products and value added services in the most effective way.
Getinge’s new financial targets for 2022-2025, an annual organic net sales growth of 4-6% and adjusted EPS growth of above 10% on average throughout the period, is well in line with our strategy and ambitions.
I have always found life science important but now I understand that it actually means everything.
The ultimate reward is when you see the patient in the clinic later on. They might not always know exactly what they have been through but you know it and the greatest feeling is when you see how well they have recovered and gone back to their families to carry on with their lives.
The perfusionists at el Hospital Universitario de Cruces received comprehensive training on the new HL 40 machine and I am happy that they were impressed by the flexibility and safety of the equipment during the procedure.
A supportive learning environment at home can be a big contributor to the overall development and growth of a child.
I feel very passionate about my job, I learn new things every day and that’s the way I like it.
Organic order intake increased by more than 20% in the third quarter, with a strong performance in all business areas and regions. Our cash flow remains strong, meaning that we have strengthened our solid financial position.
It really makes me happy to receive a message or reading a publication about positive patient outcomes where my participation may have played a role.
We are a great team achieving incredible things together. I particularly like the fact that we always face challenges together and solve them in the best possible way as a team.
The simplicity of use of the Rotaflow II facilitates safe handling even for less experienced users.
Without having to switch OR lights on and off, the surgical team benefits from better hand-eye coordination and an uninterrupted workflow. This makes it possible to have constant focus on the patient.
Surgical procedures are evolving and so does our surgical lights. The new Volista VisioNIR feature is a powerful solution to guide surgeons and secure their actions with a better hand-eye coordination when using fluorescence guided surgery. There is no longer a need to switch between on and off lighting.
Thanks to our system for sterile goods handling and surgical instrument traceability, we can ensure that the right tools are in the right place at the right time, maintaining the highest quality and guaranteed sterility.
Going to work knowing that the machines I build help provide safer care feels good inside.
During the first installations the central sterile supply department (CSSD) staff were clapping hands. Gone were the days of tracking instruments with pen, paper and label applicators. They were so happy about going digital; saving time and thereby providing better patient care
We wanted a reliable device that is easy to move around. This is crucial for enabling our team to travel to critically ill patients in places where there is no access to care resources.
It’s extra motivating to go to work every day when you know that the products you build are crucial parts of central sterile supply departments where health care staff make sure surgical instruments are being cleaned, disinfected and sterilized, ready in time for next surgery.
A competitive finance offer is a natural component for building strong partnerships.
“Our aim is to deliver world class care. Our comprehensive offering is based on decades of real-world experience in operating room and intensive care. Strong customer relationships and a deep understanding of hospital environments helped us deliver easy-to-use solutions such as Servo ventilators or Flow anesthesia machines”
In total, sales increased by 3.6% organically compared with the second quarter 2020, and the order intake declined by 6.1% organically compared with 2020 when we received very large orders of advanced ICU ventilators.
Many health care systems had long surgical waiting lists already before the COVID-19 outbreak, so a knowledge-based planning tool was underway. The pandemic spurred us to find an efficient solution quicker.
Sustainability is one of our top priorities and at the core of everything we do. Last year we announced the intention to become a CO₂ neutral company by 2025, which supports our objective to contribute to sustainable health care, environmentally as well as socially. We are honored to receive this award.
We all feel much safer now in terms of preventing the spread of viruses and health care acquired infections.
To create real improvements, we need an open ecosystem where we collaborate and share knowledge with partners and other suppliers. As I see it, this is where we can create most value.
While hospitals can take steps to hire more people and have staff work longer hours to address this backlog, they must also look at the most effective technology options to improve scheduling efficiency and utilization of resources.
After only 20 minutes of book building, the offer was oversubscribed several times and to better terms than we had dared to hope for. We will return regularly to the market with offers like this, so that more investors will have an opportunity to participate in the future.
The patient’s lungs were in very poor condition from the beginning, but the ECMO therapy gave the lungs the time they needed to heal.
The driving force is the same as Getinge’s brand promise – Passion for Life. When we enter the field this is what we carry with us inside.
I have always been proud of what I do, but the personal connection to the medicines and vaccines our bioreactors help to develop, is much stronger after my own experiences. They help bringing science to life.
It is a very severe situation and we are all exhausted but we keep on going to save more lives.
During the COVID-19 pandemic we have developed several new ways to virtually interact with our customers.
The COVID-19 pandemic and the heightened awareness of respiratory health has driven the need for personalized ventilation solutions for critically ill patients. Now more than ever, options for personalized lung protection and personalized weaning solutions are at the forefront of respiratory patient health. Getinge strives to support clinicians and patients by optimizing lung protection and delivering solutions for personalized ventilation.
More and more of our customers are heading towards a situation in which managing record-long waiting lines for surgeries is as challenging as COVID-19.
When I arrived at work one of those first traumatic days, I almost couldn’t get through the crowded hallways.
We are very pleased to offer this optimized and cost effective solution for bioreactor preparation in a time when a lot of research focus is dedicated to vaccine development and production.
I feel very proud that we have managed to keep up the close collaboration with our customers despite all restrictions the pandemic imposed on us in 2020
Getinge’s brand promise ‘Passion for Life’ also covers the lives of our employees. Also beyond COVID-19, we want to be an attractive employer offering existing and future office-based employees the opportunity to work where they can do their job best.
In times when travel and in-person contact is very limited, the possibility to step into our virtual hospital fills a crucial gap.
This partnership is an example of the extended scope of our sustainability, innovation and customer centricity and our dedication for driving Getinge to the forefront within these research areas. Ultimately, the knowledge and experience we gain can help us save more lives together with our customers
The commitment to the Science Based Target initiative is a natural next step for us. This is a good way to increase transparency on our commitment and progress. Getinge is aiming at becoming a CO₂ neutral company and has set-up dedicated activities to achieve our goal.
With the investment in Merrimack we are looking at double the installed production capacity of DPTE-BetaBag®
We have continued to support health care, and the pharmaceutical companies that are rapidly developing and manufacturing COVID-19 vaccines. We also achieved our full-year target of delivering 26,000 advanced ICU ventilators, and the demand for our ECMO therapy products remains high.
With the acquisition of Quadralene, we will bring additional value and support to our customers in their mission to reduce hospital acquired infections
While measuring continuously and non-invasively, NICCI provides a complete picture of the patient’s individual hemodynamic status – ensuring the medical staff that they never miss a beat
Especially now, when fighting with the COVID-19 pandemic, health care organizations are facing strong operational and financial challenges. Sterilization units have to reprocess surgical instruments in a flawless manner in order to manage an increasing backlog of surgeries.
The site produces approximately 230,000 units per year, which is estimated to support saving 500 lives per day
We are continuing to deepen our partnerships with hospitals and pharmaceutical companies around the world to combat COVID-19 and in the third quarter we delivered more advanced ICU ventilators than we normally do in a whole year
We've gone from a mode of ventilation where you were breathing for the baby to one now where we can breathe with the baby as well